Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
cls-ax save search
Clearside Biomedical Reports Significant Progress in ODYSSEY Phase 2b Trial of CLS-AX in Wet AMD
Published: 2023-12-14 (Crawled : 12:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 1.92%
H: 2.83%
C: -1.89%
cls-ax trial
Clearside Biomedical Completes Recruitment in ODYSSEY Phase 2b Clinical Trial of CLS-AX in Wet AMD
Published: 2023-11-01 (Crawled : 11:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.72%
H: 6.85%
C: 4.55%
cls-ax trial
Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting
Published: 2023-07-31 (Crawled : 11:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -0.82%
H: 0.0%
C: 0.0%
cls-ax presentation retina meeting potential
Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
Published: 2023-07-17 (Crawled : 13:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.0%
H: 8.33%
C: 5.83%
cls-ax trial
Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
Published: 2023-06-01 (Crawled : 11:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -1.85%
H: 9.43%
C: 5.66%
cls-ax trial
Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD
Published: 2023-04-18 (Crawled : 20:00) - biospace.com/
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 1.83%
H: 5.41%
C: 0.9%
cls-ax trial
Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings
Published: 2023-02-21 (Crawled : 12:20) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 2.9%
H: 0.0%
C: -3.52%
microinjector cls-ax trial positive
Clearside Biomedical Announces Positive 6-Month Results from OASIS Extension Study with Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD
Published: 2023-02-02 (Crawled : 12:20) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 9.09%
H: 10.12%
C: -11.31%
cls-ax extension positive results study
Clearside Biomedical Announces Positive Results in Safety, Durability and Biologic Effect in OASIS Phase 1/2a Clinical Trial of Suprachoroidal CLS-AX (axitinib injectable suspension) in Wet AMD Patients
Published: 2022-11-09 (Crawled : 12:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -7.14%
H: 21.54%
C: -1.54%
cls-ax trial positive results
Flexible Hybrid Electronics Market: 36% of Growth to Originate from North America, Evolving Opportunities with ALMAX & American Semiconductor Inc. - Technavio
Published: 2022-09-06 (Crawled : 23:00) - prnewswire.com
PCRFF | News | $8.88 -1.12% 990
|
n/a
|
| O: -2.36%
H: 1.83%
C: 0.85%
PCRFY | News | $9.52 -0.11% 420K
|
n/a
|
| O: -0.9%
H: 0.52%
C: 0.52%
AUOTY | $4.98 1.75% 59K
|
Manufacturing
|
| O: 0.0%
H: 3.71%
C: 3.47%
JBL F | $120.24 -0.54% 0.0% 1.4M
|
Electronic Technology
|
| O: -0.49%
H: 2.36%
C: 2.06%
FLEX A | $28.46 -0.25% -0.25% 2.6M
|
Electronic Technology
|
| O: -0.35%
H: 4.93%
C: 4.64%
semiconductor electronics growth
Clearside Biomedical Enters into Non-Dilutive Financing Agreement with HealthCare Royalty Partners for up to $65 Million- Transaction Supports Progression of CLS-AX Clinical Program -
Published: 2022-08-08 (Crawled : 22:00) - biospace.com/
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 2.4%
H: 1.17%
C: -4.09%
cls-ax program agreement
Clearside Biomedical Completes Dosing in OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
Published: 2022-07-26 (Crawled : 12:00) - biospace.com/
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -1.27%
H: 8.39%
C: 4.52%
cls-ax trial phase 1
MarketAxess Announces Monthly Volume Statistics for February 2022
Published: 2022-03-03 (Crawled : 12:00) - globenewswire.com
MKTX 4 | $204.16 -0.3% -0.3% 250K
|
Finance
|
| O: 0.6%
H: 0.01%
C: -4.83%
ces axes
Clearside Biomedical Announces Positive Safety Results from OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-12-21 (Crawled : 13:00) - biospace.com/
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -1.03%
H: 4.18%
C: 0.7%
treatment axitinib trial cls-ax phase 1 positive results
Clearside Biomedical Announces Completion of Dosing in Cohort 2 of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD Patients
Published: 2021-09-21 (Crawled : 12:00) - biospace.com/
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: -1.25%
H: 5.04%
C: 2.68%
phase 1 trial axitinib cls-ax dmd injection
Clearside Biomedical Announces Positive Safety Results from Cohort 1 of OASIS Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-06-15 (Crawled : 12:00) - biospace.com/
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 32.42%
H: 20.02%
C: 4.03%
treatment phase 1 positive results trial phase 3 phase 2 axitinib cls-ax dmd injection
Clearside Biomedical Announces Completion of Patient Dosing in First Cohort of Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-03-02 (Crawled : 13:01) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 3.48%
H: 0.28%
C: -4.48%
treatment phase 1 trial phase 3 phase 2 axitinib cls-ax dmd injection
Clearside Biomedical Announces CLS-AX (axitinib injectable suspension) Presentation Delivered at Angiogenesis, Exudation, and Degeneration 2021 Program
Published: 2021-02-16 (Crawled : 13:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.52%
H: 9.09%
C: 0.26%
liver axitinib cls-ax injection
Clearside Biomedical Announces First Patients Enrolled in Phase 1/2a Clinical Trial of CLS-AX (axitinib injectable suspension) for the Treatment of Wet AMD
Published: 2021-01-12 (Crawled : 13:00) - globenewswire.com
CLSD | News P | $1.33 -2.92% -3.01% 200K
|
Health Technology
|
| O: 0.54%
H: 1.36%
C: -2.44%
trial phase 3 phase 1 phase 2 treatment axitinib cls-ax dmd injection enroll
Gainers vs Losers
| 62% | 38% |
Top 10 Gainers
CSSE 4 | $0.4323 183.85% 64.77% 220M
|
Consumer Services
BOF | $1.99 70.09% 41.21% 110M
|
ILAG | $0.51 6.03% 40.62% 1.7M
|
LICN | $0.941 68.04% 40.49% 15M
|
AMST | $3.31 65.5% 39.58% 70M
|
Technology Services
MTC | $3.615 61.38% 38.04% 9.3M
|
Technology Services
WIMI | $1.15 58.53% 36.92% 19M
|
Technology Services
AIH | $0.45 12.5% 30.92% 320K
|
Health Services
MULN | News | $3.78 38.46% 27.78% 13M
|
Information
RILY | $29.86 37.48% 27.26% 12M
|
Finance
Your saved searches
Save your searches and get alerts when important news are released.